Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
about
Follicular lymphoma: 2012 update on diagnosis and managementFollicular lymphoma: 2011 update on diagnosis and managementRetreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Radioimmunotherapy with (131)i-rituximab in a patient with diffuse large B-cell lymphoma relapsed after treatment with (90)y-ibritumomab tiuxetan.A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphomaTositumomab and iodine I 131 tositumomab (Bexaar).Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisThe role of bendamustine in the treatment of indolent non-Hodgkin lymphomaRadioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphomaCancer radioimmunotherapy.Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasComparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.Follicular lymphoma: today's treatments and tomorrow's targets.Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphomaI-Tositumomab in lymphoma.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Radioactive antibodies: a historical review of selective targeting and treatment of cancer.Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Radioimmunotherapy for B-cell non-hodgkin lymphomas.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Advances and application of radioimmunotherapy in non-Hodgkin lymphoma.Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zirconium 89 in Human Lymphoma Xenografts.
P2860
Q22252956-928BEB57-1CC9-4A4A-8781-3FEF5B09DBD6Q26851450-5F99EC5F-6EAF-4A0D-9A24-217A3F16BD20Q33376503-14E30E68-AEC6-47C9-A362-90098CFCCE81Q33415748-E0AEC695-98DB-4D54-88F0-F0C865490F4EQ33427321-5DF8C96C-4E26-43F5-93CA-A8FE36D2EBE8Q33645793-1E81C13E-53E3-4E1E-93BA-968417CF9C56Q33915986-112952A3-5E0B-4A67-B589-8E3180BCE70AQ34173204-D5774423-CBFF-4F4A-B1C2-933BA0ADDBA0Q34272887-84299FCC-6C6A-4C4A-BED8-8F235CF10AE4Q34418442-6A37FD07-EBAE-45A4-A872-560D3BCC0BA2Q34631795-E04EB447-2F5C-4A96-AA6E-F7C063838B21Q34669139-4ECD45DF-D258-4AA8-8C79-179DA352A511Q35070045-F581F199-AD25-4721-904B-0BB099411DC6Q35828820-BBF7A5EB-A08A-4A27-AD80-788CCBF37CB3Q35849837-4C6F9B38-A964-4C5D-B4B0-5FE321681BC2Q36426877-4955FBD5-9CE8-404A-8C71-76F5E51E78ACQ36521854-65AB159B-1479-422B-8A75-2C4F2B32B97BQ36684500-CC718E58-19D2-4330-AACA-50BB8D9253ADQ36979699-DF81C04E-B511-489B-94C7-59B810CB247FQ37169112-65BCDE45-8611-4AF7-AA59-578B6092F96FQ37174938-A1B26372-9E15-4303-8396-5048AC4FFE09Q37290469-AAE0AD32-9937-4323-9D2F-19CA05B8540AQ37401659-F4DFA565-A9EA-4AB7-9A8B-3EFEBB7DE145Q37752447-11E4900A-1299-4B53-BE4E-D7BDA4A4AC84Q37796519-96437994-7FFE-4C0F-B67F-C281B5856B20Q37810267-64609AF1-42B4-496C-A207-E74EE6E74141Q37877728-B19AADE1-52EC-4171-B21A-AD0F90F516BDQ38019790-4A61135F-4F29-42F9-9CE1-D9821DCCF9DCQ38473731-623FB441-D1DD-4639-A8CE-C4C050F998AFQ39591787-C298E531-665C-468C-9D8A-D95B8353FF4DQ49953473-30DB49B2-FEB3-4EA3-A66E-1C4EA41B34CA
P2860
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@ast
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@en
type
label
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@ast
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@en
prefLabel
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@ast
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@en
P2093
P356
P1476
Re-treatment with I-131 tositu ...... esponded to I-131 tositumomab.
@en
P2093
John P Leonard
Mark S Kaminski
Richard L Wahl
Stephanie A Gregory
Stewart Kroll
Susan J Knox
P304
P356
10.1200/JCO.2005.01.0892
P407
P50
P577
2005-10-03T00:00:00Z